Article in GEN on Biovista’s participation in the Eurpean “p-medicine” project. Drug repositioning specialist Biovista’s European affiliate has been awarded a $0.5 million grant to fund its participation in the European Commission’s €13.3 million (roughly $19.7 million), four-year p-medicine project focused on developing new tools and virtual physiological human (VPH) models to speed the development … Read More
News
Biovista Inc. Receives Prestigious EU Grant to use its Drug Repositioning Platform for Personalized Medicine
CHARLOTTESVILLE, Virginia and ATHENS, Greece, May 5, 2011 /PRNewswire/ — Biovista Inc. announced today that it’s EU affiliate has been awarded a prestigious grant worth $0.5 million, for research and development in the area of personalized medicine. The “p-medicine” project is a four-year, 13.3 million Euro co-funded effort under the European Community’s 7th Framework Programme … Read More
Biovista Announces Research Collaboration With a Major Pharmaceutical Company
CHARLOTTESVILLE, Virginia, April 27, 2011 /PRNewswire/ — Biovista announced today that it has entered into a research collaboration agreement with Novartis. The collaboration is focused on identifying new indications for a number of undisclosed Novartis compounds using Biovista’s Clinical Outcome Search Space (COSS) technology. The terms of the agreement include an upfront payment and success-based … Read More
The Scientist: Teaching an Old Drug New Tricks
Biotech companies hope to turn the practice of finding novel uses for existing compounds into big business. Andreas and Aris Persidis love to tackle big problems. As graduate students in the 1980s, the two brothers—a naval architect and a biochemist, respectively—would spend long nights knocking around ideas for how to engineer a better propeller or … Read More
Drug Repositioning podcast
Drug repositioning as a viable business strategy. Biovista’s President A. Persidis interview to GEN’s editor in chief, John Sterling. “Prompted by the need to refurbish their pipelines at lower costs and to drive and sustain future profits, drug companies have turned to drug repositioning, or repurposing, as a means of drug rediscovery. The process of … Read More